Federal Court Dismisses VIOXX(R) Securities Class Action.WHITEHOUSE STATION, N.J. -- Today, Merck & Co., Inc. said a federal judge in New Jersey dismissed with prejudice a consolidated securities class action filed by investors against the Company in connection with disclosures regarding VIOXX Vi·oxx A trademark for the drug rofecoxib. Vioxx® Rofecoxib Pain management A COX-2 inhibitor used to manage osteoarthritic pain, acute pain in adults, primary dysmenorrhea. See COX-2 inhibitor. . In his April 12 ruling, Judge Stanley Chesler of the U.S. District Court in Newark found that the securities action should be dismissed because all of the plaintiffs' claims were time-barred under the applicable statutes of limitations. About Merck Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet un·met adj. Not satisfied or fulfilled: unmet demands. medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com. Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q Form 10-Q See 10-Q. and Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. , which the Company incorporates by reference. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion